Skip to main content

Table 3 Summary of selected drugs in testing and clinical trials targeting B7-H3 (ClinicalTrials.gov) and their mechanisms

From: New frontiers in immune checkpoint B7-H3 (CD276) research and drug development

List of drugs/agents

Mechanisms of Targeting B7-H3

Status

Cancer types

Company/organization

B7-H3 TriKE(GTB-5550)

Natural Killer (NK)- cell-based therapy/ADCC

Phase I trial scheduled for 2022

Multiple myeloma

GT BIOPHARMA, Inc

TAA06 Injection

B7-H3-targeted CAR-T therapy

FDA approved drug (Orphan drug)

Neuroblastoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd

131I-omburtamab

radiolabeled mAb targeting B7-H3

FDA approval?

Neuroblastoma

Y-mAbs Therapeutics, Inc

Autologous B7-H3-CAR T

B7-H3-targeted CAR-T therapy

Phase I

Epithelial Ovarian Cancer

UNC Lineberger Comprehensive Cancer Center

DS-7300a

B7-H3 Antibody Drug Conjugate (ADC),

Phase II

Extensive-Stage Small Cell Lung cancer (SCLC)

Daiichi Sankyo, Inc

MGC018/ MGA012

Anti-B7-H3 Antibody Drug Conjugate

Phase I/II

Advanced Solid tumors

MacroGenics

DS-7300a

anti-B7H3 antibody

Phase I/II

Advanced Solid Malignant Tumors

Daiichi Sankyo Co., Ltd

B7-H3-CAR T

B7-H3-targeted CAR-T therapy

Phase I

Recurrent Glioblastoma Multiforme (GBM)

Crystal Mackall, MD, Stanford University

Neoadjuvant Nivolumab Plus Ipilimumab

Immunotherapy

Phase 1

Malignant Peripheral Nerve Sheath Tumor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

177Lu-DTPA-omburtamab

Radioimmunotherapy (a radioactive labelling of a murine monoclonal antibody targeting B7-H3

Phase I/II

Medulloblastoma

Y-mAbs Therapeutics